A fluorescent bead-based multiplex assay for the detection of Brucella sp. specific antibodies in canine serum

一种基于荧光微珠的多重检测方法,用于检测犬血清中布鲁氏菌属特异性抗体

阅读:1

Abstract

INTRODUCTION: The zoonotic pathogen, Brucella canis, causes brucellosis in dogs. Infection with B. canis is usually diagnosed by serological testing. We developed a fluorescent bead-based multiplex assay for detection of B. canis specific antibodies in canine serum. The assay consists of two antigens detected simultaneously by canine serum antibodies. One antigen, BP26, was selected from a set of immunodominant proteins identified through western blot and proteomics analysis. The second antigen, PO1, is a 17 amino acid peptide derived from B. canis Omp31. METHODS: Dog sera from diagnostic submissions were tested in parallel with a reference assay consisting of a rapid slide agglutination test (2ME-RSAT) and an agar gel immunodiffusion test (AGID II). A Bayesian latent class model (BLCM) was utilized to determine sensitivity and specificity of both assays. For the model to be identifiable, two groups with differing prevalence were included; one group was composed of 1,192 diagnostic submissions, and the second group was composed of 390 samples submitted for export purposes. RESULTS: The seroprevalence of B. canis specific antibodies in these two groups was estimated to be 16.1% (95% CI, 12.6-19.3%) and 0.1% (95%, 0.0-0.6%), respectively. Diagnostic sensitivity and specificity of the two-antigen assay for detecting B. canis specific antibodies were 91.6% (95% CI, 85.2-98.0%) and 94.9% (95% CI, 92.3-96.9%), respectively. DISCUSSION: The addition of a third cytoplasmic antigen further increased assay sensitivity. The Canine Brucella Multiplex assay is a novel and quantitative diagnostic tool for detecting B. canis antibodies in canine serum to aid in the diagnosis of brucellosis in dogs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。